İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi · May 31, 2026
Multidimensional Impact of Polypharmacy on Cognitive Function, Depression, Functionality, and Quality of Life in Older Adults: A Cross-Sectional Study
By Dansuk E, Menek B
Objective: This study aimed to evaluate the effects of polypharmacy on cognitive function, depression levels, activities of daily living, and qualityof life in individuals aged 65 years and older.Material and Methods: This cross-sectional study included a total of 164 older adults (mean age: 73 years) who presented to the geriatricoutpatient clinic of a university hospital. Participants were divided into two groups based on the number of medications used: the polypharmacygroup (≥5 medications) and the non-polypharmacy group (0–4 medications). Cognitive function was assessed using the Mini-Mental StateExamination (MMSE), depression with the Geriatric Depression Scale (GDS), activities of daily living with the Barthel Index (BI), and quality of lifewith the WHOQOL-OLD scale.Results: No statistically significant differences were found between the groups in terms of cognitive function (p = 0.910), depression levels (p =0.585), or activities of daily living (p = 0.656). However, the non-polypharmacy group showed significantly higher scores in the WHOQOL-OLDtotal score (p = 0.013), as well as in the subdomains of social participation (p = 0.038), death and dying (p = 0.046), and intimacy (p = 0.046).Conclusion: Polypharmacy may negatively affect quality of life in older adults; however, its cognitive and functional effects may vary dependingon sample characteristics. These findings highlight the importance of conducting comprehensive and individualized assessments of polypharmacyin geriatric populations.